Investors

Press Releases

ObsEva SA to present at the Jefferies Virtual Healthcare Conference June 3rd, 2020

May 29, 2020

Geneva, Switzerland and Boston, MA – May 29, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and…

Read more

ObsEva Annual General Meeting 2020

May 8, 2020

Geneva, Switzerland and Boston, MA – May 8, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization…

Read more

ObsEva Announces First Quarter 2020 Financial Results and Business Update

May 5, 2020

No impact from COVID-19 expected on timing of PRIMROSE 1 and 2 and PROLONG trial readouts, enrollment of new patients…

Read more

ObsEva Announces Publication of Abstracts from Phase 2b EDELWEISS Trial of Linzagolix in Endometriosis

April 22, 2020

Significant improvement in quality of life outcomes maintained or increased after 52 weeks of treatment with linzagolix Small, expected, non-clinically…

Read more

ObsEva to Increase Issued Share Capital by Creating Additional Treasury Shares

April 14, 2020

Geneva, Switzerland and Boston, MA – Tuesday 14 April, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss…

Read more

ObsEva SA Announces New Interim Chief Financial Officer

April 6, 2020

Geneva, Switzerland and Boston, MA – April 6, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and…

Read more

ObsEva SA: New Date Announcement for AGM

March 27, 2020

Geneva, Switzerland and Boston, MA – March 27, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and…

Read more

ObsEva Provides Update Related to COVID-19 Pandemic

March 23, 2020

  Patient safety remains the top priority PRIMROSE 1 and PRIMROSE 2 trial results expected to be announced in Q2:20,…

Read more

ObsEva SA Link to Annual Report 2019

March 5, 2020

Geneva, Switzerland and Boston, MA – March 5, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company…

Read more

ObsEva Announces Year End 2019 Financial Results and Business Update

March 5, 2020

Primary endpoint achieved in 94% of women in linzagolix Phase 3 PRIMROSE 2 trial in uterine fibroids Linzagolix Phase 3…

Read more
 
 

Sign up for news

 
 

* Type:


InvestorHCPNursePayerHospital PharmacistRetail PharmacistOther












Read our privacy policy here.


 

Are you sure you want to leave ObsEva.com?

We’re sorry to see you go. Choose one of the following actions to stay on the site or leave.

Continue to link

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue